Orion Oyj (OTCMKTS:ORINY - Get Free Report) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 600 shares, an increase of 20.0% from the February 13th total of 500 shares. Currently, 0.0% of the company's shares are short sold. Based on an average trading volume of 700 shares, the days-to-cover ratio is currently 0.9 days.
Analyst Ratings Changes
Separately, Nordea Equity Research cut shares of Orion Oyj to a "hold" rating in a report on Tuesday, February 4th.
View Our Latest Analysis on ORINY
Orion Oyj Price Performance
Shares of ORINY remained flat at $30.57 during trading hours on Friday. 145 shares of the stock were exchanged, compared to its average volume of 3,307. Orion Oyj has a 52-week low of $17.50 and a 52-week high of $30.57. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. The firm has a 50 day moving average price of $27.42 and a two-hundred day moving average price of $25.59. The stock has a market cap of $8.63 billion, a P/E ratio of 24.26 and a beta of 0.25.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 earnings per share for the quarter. The business had revenue of $463.41 million for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. On average, analysts expect that Orion Oyj will post 1.18 EPS for the current year.
Orion Oyj Increases Dividend
The business also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Investors of record on Monday, April 7th will be given a dividend of $0.4478 per share. The ex-dividend date of this dividend is Monday, April 7th. This is a positive change from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio (DPR) is 24.00%.
About Orion Oyj
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
See Also
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
